Prime Medicine Estimates $61.2 Million In Liquidity With Liver Trial Results Expected In 2027

Prime expects funding to last into 2027 and plans an approval application for its chronic granulomatous disease treatment.

Share
Prime Medicine Estimates $61.2 Million In Liquidity With Liver Trial Results Expected In 2027

Prime Medicine, which develops treatments that rewrite DNA to correct inherited diseases, estimated approximately $61.2 million in cash, cash equivalents and short-term investments at September 30, according to an SEC filing Tuesday. The preliminary, unaudited estimate comes as the company expects initial patient results from its liver-disease programs in 2027.

September Cash Excludes Restricted Funds

The September balance excludes approximately $13.7 million in restricted cash. Prime is still completing its quarter-end accounts, and final adjustments could materially change the estimates.

Prime's accompanying corporate presentation put its June 30 balance at $108.8 million and said funding is expected to last into 2027. That June figure includes restricted cash as well as cash, cash equivalents and investments, unlike the September estimate.

Liver Programs Approach Patient Readouts

Prime's Wilson disease trial is underway, with initial results expected in 2027. The early-stage study tests PM577a through a single intravenous infusion in adults and adolescents carrying the H1069Q mutation; its main goals are safety and tolerability.

Wilson disease disrupts the body's handling of copper, allowing toxic accumulation in the liver and brain. Prime plans to use its work on PM577a to help develop treatments for other Wilson disease mutations and additional liver diseases.

The company also expects initial PM647 patient results in 2027 after receiving clearance to begin an early-stage trial for alpha-1 antitrypsin deficiency. That inherited disorder can damage both lungs and liver. The planned study includes adults with lung-only disease and adults with liver involvement, again focusing first on safety and tolerability.

Partners Fund Work Beyond Liver

Prime's internal programs sit alongside research and licensing partnerships. Its September 2024 agreement with Bristol Myers Squibb supports development of T-cell treatments edited outside the body for cancer and autoimmune diseases.

The agreement provided $110 million upfront, including a $55 million equity investment, and carries more than $3.5 billion in potential milestone payments plus royalties on net sales. Those future payments are contingent opportunities, rather than cash already received.

The Cystic Fibrosis Foundation also supports Prime's treatment research through funding agreements signed in January 2024 and July 2025 for up to $15 million and $24 million, respectively. Prime is pursuing approaches that correct mutations or insert a larger gene sequence to restore function.

Prime plans to submit an FDA approval application for PM359, its chronic granulomatous disease treatment, in the first half of 2027 following final alignment with the agency. That filing and the anticipated liver-trial readouts share the year into which management expects its funding to extend.

Sources